17624-36-1Relevant articles and documents
Synthesis, characterization, and crystal structures of tris(2-pyridyl) phosphine sulfide and selenide
Kharat, Ali Nemati,Bakhoda, Abolghasem,Hajiashrafi, Taraneh,Abbasi, Alireza
, p. 2341 - 2347 (2010)
We report the synthesis and structural determinations of tris(2-pyridyl)phosphine sulfide and selenide, which were prepared by the reaction of 2-lithiopyridine with phosphorus trichloride at -100°C, and treatment of resulted (2-pyridyl)phosphine with elemental sulfur or selenium in hot toluene. These compounds were characterized by elemental analysis, melting point determination, mass spectroscopy, IR, 1H, and 31P NMR spectroscopies. Furthermore, the molecular structures of tris(2-pyridyl)phosphine sulfide and selenide were determined by single crystal X-ray analysis and compared with the structures of tris(2-pyridyl)phosphine and tris(2-pyridyl)phosphine oxide. Copyright Taylor & Francis Group, LLC.
Chemoselective Ketone Synthesis by the Addition of Organometallics to N-Acylazetidines
Liu, Chengwei,Achtenhagen, Marcel,Szostak, Michal
supporting information, p. 2375 - 2378 (2016/06/09)
A general and highly chemoselective method for the synthesis of ketones by the addition of organometallics to N-acylazetidines via stable tetrahedral intermediates is reported for the first time. The transformation is characterized by its wide substrate scope and exquisite selectivity for the ketone products even when a large excess of nucleophilic reagents is used. Even of broader interest is the use of N-acylazetidines as bench-stable, readily available amide acylating reagents, in which the reactivity is controlled by amide pyramidalization and strain of the four-membered ring to afford synthetically valuable building blocks.
IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF ANXIETY AND RELATED DISEASES
-
Page/Page column 33, (2008/06/13)
This invention relates to imidazole derivatives V of formula (I), pharmaceutical compositions containing these compounds, and methods of treatment therewith. The compounds of the invention are useful in the treatment of central nervous system diseases and disorders, which are responsive to modulation of the GABAAreceptor complex, and in particular for combating anxiety and related diseases.